MHRA and Medical Cannabis Licensing in the UK

The MHRA’s Role in Regulating Cannabis-Based Medicines

• The MHRA is responsible for licensing medicinal products in the UK including cannabis-based medicines
• Full marketing authorisations require clinical evidence meeting standard EMA-equivalent criteria
• Unlicensed specials and named-patient imports operate under a different regulatory pathway
• The MHRA publishes guidance specifically for cannabis-based medicinal products (CBMPs)

The Medicines and Healthcare products Regulatory Agency sits at the centre of the UK’s medicines regulation framework. For medical cannabis, the MHRA has developed specific guidance that recognises the unusual regulatory history of cannabis whilst maintaining the standards expected of all medicinal products placed on the UK market.

Licenced vs Unlicensed Cannabis Products

• Epidyolex and Sativex hold full MHRA marketing authorisations
• The majority of prescribed cannabis medicines in the UK are unlicensed specials or imports
• Unlicensed products can be prescribed under the Medicines Act’s special provisions
• Prescribers carry greater clinical responsibility when using unlicensed products

The distinction between licensed and unlicensed cannabis medicines has significant implications for both prescribers and importers. Licensed products have been through rigorous clinical evaluation; unlicensed products have not. This does not mean unlicensed products are unsafe, but it does mean that clinical governance arrangements must be robust, and that prescribers must be satisfied that use is appropriate for the individual patient.

Wholesale Dealer Authorisation and Import Licences

• Wholesale dealers of unlicensed cannabis imports must hold a Wholesale Dealer’s Authorisation
• Import licences for controlled drug consignments are issued by the Home Office, not the MHRA
• The MHRA conducts Good Distribution Practice inspections of wholesale operations
• GDP compliance is a prerequisite for maintaining a Wholesale Dealer’s Authorisation

Operating as a licensed importer and wholesaler of medical cannabis in the UK requires engagement with two separate regulatory bodies. The MHRA governs the medicinal product aspects of the business, while the Home Office controls the controlled drug aspects. Building a compliance framework that satisfies both regulators simultaneously is one of the key operational challenges for new market entrants.

Post-Brexit Regulatory Divergence

• The UK regulates medicines independently from the European Medicines Agency since 2021
• EU-GMP certificates issued by EMA-recognised bodies are currently recognised by the MHRA
• Future divergence in standards remains a possibility under the MHRA’s independent agenda
• UK-specific labelling and packaging requirements differ from EU requirements

Post-Brexit regulatory divergence is a live issue for cannabis medicine importers sourcing EU-GMP certified product from European cultivators. Current recognition arrangements provide a degree of continuity, but the MHRA has signalled its intent to develop distinctly UK-appropriate standards over time. Importers should monitor MHRA consultations closely and engage with trade associations to shape emerging policy.